Jeph Herrin, PhD
About
Research
Publications
Featured Publications
Trends in Racial and Ethnic Disparities in Barriers to Timely Medical Care Among Adults in the US, 1999 to 2018
Caraballo C, Ndumele CD, Roy B, Lu Y, Riley C, Herrin J, Krumholz HM. Trends in Racial and Ethnic Disparities in Barriers to Timely Medical Care Among Adults in the US, 1999 to 2018. JAMA Health Forum 2022, 3: e223856. PMID: 36306118, PMCID: PMC9617175, DOI: 10.1001/jamahealthforum.2022.3856.Peer-Reviewed Original ResearchConceptsTimely medical careSerial cross-sectional studyNational Health Interview SurveyCross-sectional studyHealth Interview SurveyMedical careLack of transportationEthnic disparitiesHispanics/LatinosWhite individualsEthnicity groupsInterview SurveyCost of careSelf-reported raceStudy cohortClinic hoursMAIN OUTCOMEMedical officesCarePrevalenceLatino individualsBlack individualsSignificant differencesSignificant increasePopulation groupsIdentifying high-value care for Medicare beneficiaries: a cross-sectional study of acute care hospitals in the USA
Herrin J, Yu H, Venkatesh AK, Desai SM, Thiel CL, Lin Z, Bernheim SM, Horwitz LI. Identifying high-value care for Medicare beneficiaries: a cross-sectional study of acute care hospitals in the USA. BMJ Open 2022, 12: e053629. PMID: 35361641, PMCID: PMC8971780, DOI: 10.1136/bmjopen-2021-053629.Peer-Reviewed Original ResearchConceptsAcute care hospitalsHigh-value careStar hospitalsCare hospitalMedicare spendingEligible Medicare patientsRetrospective observational studyCross-sectional studyNon-teaching statusHigh-quality careHigh-quality hospitalsLow-cost hospitalsHigh-cost hospitalsCharacteristics of hospitalsValue of careSecondary outcomesPrimary outcomeMedicare patientsObservational studyMedicare beneficiariesHospitalQuality careOverall star ratingHospital ValueComparative Effectiveness of Machine Learning Approaches for Predicting Gastrointestinal Bleeds in Patients Receiving Antithrombotic Treatment
Herrin J, Abraham NS, Yao X, Noseworthy PA, Inselman J, Shah ND, Ngufor C. Comparative Effectiveness of Machine Learning Approaches for Predicting Gastrointestinal Bleeds in Patients Receiving Antithrombotic Treatment. JAMA Network Open 2021, 4: e2110703. PMID: 34019087, PMCID: PMC8140376, DOI: 10.1001/jamanetworkopen.2021.10703.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAnticoagulantsAntifibrinolytic AgentsAtrial FibrillationClinical Decision-MakingCohort StudiesCross-Sectional StudiesFemaleFibrinolytic AgentsGastrointestinal HemorrhageHumansMachine LearningMaleMiddle AgedMyocardial IschemiaPredictive Value of TestsRetrospective StudiesRisk AssessmentThienopyridinesUnited StatesVenous ThromboembolismYoung AdultConceptsGastrointestinal bleedingIschemic heart diseaseCross-sectional studyThienopyridine antiplatelet agentAntithrombotic treatmentVenous thromboembolismAntiplatelet agentsRandom survival forestStudy cohortAtrial fibrillationValidation cohortHeart diseaseHAS-BLED risk scoreRetrospective cross-sectional studyCox proportional hazards regressionHAS-BLED scorePrior GI bleedPatients 18 yearsCohort of patientsEntire study cohortProportional hazards regressionOptumLabs Data WarehouseMedicare Advantage enrolleesPositive predictive valueRisk prediction modelPopulation well-being and electoral shifts
Herrin J, Witters D, Roy B, Riley C, Liu D, Krumholz HM. Population well-being and electoral shifts. PLOS ONE 2018, 13: e0193401. PMID: 29529049, PMCID: PMC5846778, DOI: 10.1371/journal.pone.0193401.Peer-Reviewed Original Research
2024
413-P: Comparative Effectiveness of Glucose-Lowering Agents on Kidney Outcomes in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk
NEUMILLER J, HERRIN J, SWARNA K, POLLEY E, GALINDO R, UMPIERREZ G, DENG Y, MICKELSON M, MCCOY R. 413-P: Comparative Effectiveness of Glucose-Lowering Agents on Kidney Outcomes in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk. Diabetes 2024, 73 DOI: 10.2337/db24-413-p.Peer-Reviewed Original ResearchPatient-Centered Outcomes Research InstituteModerate CVD riskKidney composite outcomeAssociated with lower riskGLP-1RACVD riskType 2 diabetesKidney outcomesComposite outcomeKidney diseaseLow riskHigh riskInitiation of kidney replacement therapyEffects of glucose-lowering agentsCardiovascular diseaseHigh risk of cardiovascular diseaseAssociated with increased riskBaseline CVD riskAssociated with higher riskRisk of cardiovascular diseaseGlucose-lowering agentsCare of peopleIncident kidney diseaseModerate cardiovascular riskTarget trial frameworkPrimary outcomes of the enhanced, EHR-facilitated cancer symptom control (E2C2) cluster-randomized, stepped wedge, pragmatic trial.
Cheville A, Pachman D, Kroenke K, Herrin J, Grzegorczyk V, Mitchell S, Griffin J, Ridgeway J, Austin J, Smith A, Chlan L, Tofthagen C, Ruddy K. Primary outcomes of the enhanced, EHR-facilitated cancer symptom control (E2C2) cluster-randomized, stepped wedge, pragmatic trial. Journal Of Clinical Oncology 2024, 42: lba12006-lba12006. DOI: 10.1200/jco.2024.42.17_suppl.lba12006.Peer-Reviewed Original ResearchElectronic patient-reported outcome measuresCollaborative care modelElectronic health recordsNumerical rating scaleCluster-randomizedPragmatic trialSymptom burdenAssociated with adverse health outcomesCCM-based interventionsPatient-reported outcome measuresHealth service outcomesSelf-management informationClinician decision supportPrimary outcomeCancer type or stageMulti-state health systemCancer symptom controlCluster randomized trialMedical oncology clinicAdverse health outcomesUsual careCare modelCare teamSymptom managementSymptom scoresSPPADE symptom prevalence and severity in a diverse sample of patients living with metastatic cancers.
Pachman D, Ruddy K, Grzegorczyk V, Kroenke K, Griffin J, Ridgeway J, Chlan L, Tofthagen C, Leventakos K, Strand J, Austin J, Smith A, Mitchell S, Herrin J, Cheville A. SPPADE symptom prevalence and severity in a diverse sample of patients living with metastatic cancers. Journal Of Clinical Oncology 2024, 42: 11108-11108. DOI: 10.1200/jco.2024.42.16_suppl.11108.Peer-Reviewed Original ResearchSymptom burdenHigh school educationDiverse sample of patientsAmerican Indian/Alaska Native (AI/ANSymptom management interventionsHigh symptom burdenPhysical function impairmentComposite scoreCancer symptom controlTotal symptom burdenSchool educationComposite mean scoresSymptom interventionMetastatic diseaseMetastatic cancerSymptom prevalenceSample of patientsSymptom surveyEmployment statusDisability statusMean scoreICD codesCancer typesManagement interventionsSymptom controlComparative Effectiveness of GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy
Barkmeier A, Herrin J, Swarna K, Deng Y, Polley E, Umpierrez G, Galindo R, Ross J, Mickelson M, McCoy R. Comparative Effectiveness of GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy. Ophthalmology Retina 2024 PMID: 38735641, DOI: 10.1016/j.oret.2024.05.003.Peer-Reviewed Original ResearchThe PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVID
Krumholz H, Sawano M, Bhattacharjee B, Caraballo C, Khera R, Li S, Herrin J, Coppi A, Holub J, Henriquez Y, Johnson M, Goddard T, Rocco E, Hummel A, Al Mouslmani M, Putrino D, Carr K, Carvajal-Gonzalez S, Charnas L, De Jesus M, Ziegler F, Iwasaki A. The PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVID. The American Journal Of Medicine 2024 PMID: 38735354, DOI: 10.1016/j.amjmed.2024.04.030.Peer-Reviewed Original ResearchLC trialPROMIS-29Participants' homesTargeting viral persistencePlacebo-controlled trialDouble-blind studyElectronic health recordsCore Outcome MeasuresLong COVIDEQ-5D-5LRepeated measures analysisEvidence-based treatmentsPhase 2Double-blindParticipant-centred approachStudy drugPrimary endpointSecondary endpointsCommunity-dwellingHealth recordsHealthcare utilizationContiguous US statesViral persistencePatient groupDrug treatmentCalculation of Overall Hospital Quality Star Ratings With and Without Inclusion of the Peer Grouping Step
Gettel C, Bagshaw K, Qin L, Lin Z, Rothenberg E, Omotosho P, Goutos D, Herrin J, Suter L, Schreiber M, Fleisher L, Myers R, Spivack S, Venkatesh A. Calculation of Overall Hospital Quality Star Ratings With and Without Inclusion of the Peer Grouping Step. JAMA Network Open 2024, 7: e2411933. PMID: 38753326, PMCID: PMC11099678, DOI: 10.1001/jamanetworkopen.2024.11933.Peer-Reviewed Original ResearchConceptsCenters for Medicare & Medicaid ServicesCross-sectional studyHospital characteristicsHigher star ratingsStar ratingsOverall hospital qualityLowest-performing hospitalsOverall star ratingQuality star ratingsHospital star ratingsStar Ratings scoresHospital qualityHospital performanceStratified hospitalsMedicaid ServicesMain OutcomesFace validityPeer groupPeer group approachPrimary outcomePeer comparisonHospitalRating scoresPeerMeasurement group
Links & Media
News
- July 02, 2024
Yale Faculty Members Named to JACC Editorial Board
- April 03, 2024
Assessing Equity Measures in Hospital Readmissions
- April 01, 2024
Yale Faculty Present Groundbreaking Clinical Research at the 2024 American College of Cardiology Scientific Sessions
- May 16, 2023
Yale Study Documents Staggering Toll of Health Disparities for Black Americans